Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.67 |
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855350 | 0.96 | MAPT (0.61) | LMNAMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL29803356 | 0.91 | ALDH1A1 (0.67) | LMNAMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL6808636 | 0.91 | ALDH1A1 (0.67) | LMNAMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL1611598 | 0.88 | LMNA (0.63) | LMNAMAPTALDH1A1SMN1; SMN2SLC6A5 | |
| SCHEMBL3258234 | 0.86 | MAPT (0.65) | LMNAMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL113816 | 0.86 | MAPT (0.70) | LMNAMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL15658785 | 0.85 | LMNA (0.56) | LMNAMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL15658784 | 0.85 | LMNA (0.56) | LMNAMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL27178641 | 0.85 | MAPT (0.68) | LMNAMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL6969829 | 0.84 | ALDH1A1 (0.55) | LMNAMAPTALDH1A1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011163279-A3 | LOW-POWER WIRELESSLY-LINKED RFID TRACKING SYSTEM | ROSE MARK D (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2217583-B1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-11-30 | — | — | EP | disclosed |
| US-20110086863-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2011-04-14 | — | — | US | disclosed |
| US-7790727-B2 | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2010-09-07 | — | — | US | disclosed |
| EP-2217583-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090131452-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-05-21 | — | — | US | disclosed |
| WO-2009056632-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-05-07 | — | — | WO | disclosed |
| EP-0946539-B1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-13 | — | — | EP | disclosed |
| US-6599904-B2 | 5-HT6 receptor antagonists are believed to be of potential use in the treatment of certain CNS disorders; cognitive memory enhancement | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-29 | — | — | US | disclosed |
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | SMITHKLINE BEECHAM P.L.C. | 2003-04-10 | — | — | US | disclosed |
| US-6423717-B1 | NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-23 | — | — | US | disclosed |
| EP-0946539-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | disclosed |
| US-5789412-A | 5-HYDROXYTRYPTAMINE (SEROTONIN) RECEPTOR ANTAGONISTS FOR THE CURATIVE OR PREVENTIVE TREATMENT OF PAIN, DEPRESSION, OBSESSIVE COMPULSIVE DISORDERS, ANXIETY OR PANIC ATTACK, OR CANCER | PIERRE FABRE MEDICAMENT (FR) | 1998-08-04 | — | — | US | disclosed |
| WO-1998027081-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | disclosed |
| EP-0773937-A1 | NOVEL ARYL PIPERAZINE-DERIVED PIPERAZIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | PIERRE FABRE MEDICAMENT (FR) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996002525-A1 | NOVEL ARYL PIPERAZINE-DERIVED PIPERAZIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | PIERRE FABRE MEDICAMENT (FR) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | TPMT, MPST, STS | LMNA 3618/4885MAPT 553/4885ALDH1A1 2516/4885 |
| US-20090131452-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR1D, HTR1B | LMNA 3918/4885MAPT 4475/4885ALDH1A1 1417/4885 |
| US-20110086863-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR1D, HTR1B | LMNA 3984/4885MAPT 4509/4885ALDH1A1 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.